Crestor European Label Changes Prompt FDA Public Health Advisory
Executive Summary
FDA is stressing that physicians should carefully read labeling for AstraZeneca's Crestor after changes to the statin's European label
You may also be interested in...
Crestor DTC Ads To Resume Following Safety Labeling Update
AstraZeneca will resume direct-to-consumer ads for Crestor following the completion of labeling revisions that emphasize an increased risk of rhabdomyolysis, especially at the statin's highest approved dose
Crestor DTC Ads To Resume Following Safety Labeling Update
AstraZeneca will resume direct-to-consumer ads for Crestor following the completion of labeling revisions that emphasize an increased risk of rhabdomyolysis, especially at the statin's highest approved dose
Vytorin Managed Care Outlook More Positive Than Crestor, Survey Finds
Merck/Schering-Plough's Vytorin is likely to have favorable formulary coverage with approximately 38% of managed care payors within the first year of launch, according to a survey by Prudential Equity Group